3a,4b,3a-Galactotetraose
CAS: 56038-38-1
Ref. 3D-OG05062
| 1mg | 180.00 € | ||
| 2mg | 249.00 € | ||
| 5mg | 396.00 € | ||
| 10mg | 633.00 € | ||
| 25mg | 1,013.00 € |
Product Information
- Gal-a1,3Gal-b-1,4Gal-a-1,3Gala1,3-b1,4-a1,3 Galactotetraose
The acetolysis of carrageenan produces a polymer homologous series of oligosaccharides, [Gal α1,3 Gal, Gal β1,4 Gal], [Gal α1,3 Gal β1,4 Gal, Gal β14, Gal α1,3 Gal], [Gal α1,3 Gal β1,4 Gal α1,3 Gal, Gal β1,4Gal α1,3Gal β1,4Gal] etc. (Lawson, 1968). This is significant as it provides an entry to the α-gal series or Galili antigens due to the fact that the disaccharide Galα1,3 Gal can be isolated in quantity. The distribution of the full α-gal epitope (Galα1-3Galβ1-4GlcNAc-R) is unique in mammals, being abundantly expressed on glycoconjugates of non-primate mammals, prosimians and New World monkeys. In contrast, the α-gal epitope is not expressed on glycoconjugates of Old World monkeys, apes and humans; instead, they produce the natural anti-Gal antibody that specifically binds the α-epitope. Anti-Gal mediates the rejection of pig xenograft organs in humans and monkeys by binding α-gal epitopes on the pig cells, inducing complement mediated destruction and antibody dependent cell mediated destruction. This barrier to xenotransplantation has been eliminated by producing α1,3 glycosyltransferase to knockout pigs. Since anti-Gal is ubiquitous in humans, the α-gal epitope has clinical potential in the production of vaccines expressing α-epitopes that can be targeted to antigen presenting cells (APC), thereby increasing the immunogenicity of viral and other microbial vaccines (Macher, 2008).
Chemical properties
Technical inquiry about: 3D-OG05062 3a,4b,3a-Galactotetraose
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
